Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy

References

• Zoni-Berisso M, Lercari F, Carazza T, et al. Epidemiology of atrial fibrillation: European perspective. Clinical Epidemiology. 2014;6:213–220.
   PubMed Web of Science ®Google Scholar
• Ganz LI, Spragg D Epidemiology of and risk factors for atrial fibrillation UpToDate®2017 [updated 2020 Jan 08; cited 2020 Jun 22]. Available from: https://www.uptodate.com/contents/epidemiology-of-and-risk-factors-for-atrial-fibrillation.
   Google Scholar
• Cea-Calvo L, Redon J, Lozano JV, et al. Prevalencia de fibrilación auricular en la población española de 60 o más años de edad. Estudio PREV-ICTUS. Revista Española de Cardiología. 2007;60(6):616–624.
   PubMedGoogle Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Banerjee A, Boriani G, et al., Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–1201.
   PubMed Web of Science ®Google Scholar
• Lip G, Freedman B, De Caterina R, et al. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost. 2017;117(7):1230–1239.
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA. 2001;285(22):2864–2870.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263–272.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al., Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al., Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al., Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Sun Z, Liu Y, Zhang Y, et al. Differences in safety and efficacy of oral anticoagulants in patients with non-valvular atrial fibrillation: A Bayesian analysis. Int J Clin Pract. 2018;73(4):e13308.
   Web of Science ®Google Scholar
• Wolfe Z, Khan SU, Nasir F, et al. A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants. J Thromb Haemost. 2018;16(7):1296–1306.
   PubMed Web of Science ®Google Scholar
• De Caterina R, Ageno W, Agnelli G, et al. The non-vitamin K antagonist oral anticoagulants in heart disease: section V—special situations. Thromb Haemost. 2019;119(1):14–38.
   PubMed Web of Science ®Google Scholar
• Mazurek M, Huisman MV, Rothman KJ, et al. Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF phase II registry. Thromb Haemost. 2017;117(12):2376–2388.
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Basic E, Hohmann C, et al. Effectiveness and safety of non–vitamin K oral anticoagulants in comparison to phenprocoumon: data from 61,000 patients with atrial fibrillation. Thromb Haemost. 2018;118(3):526–538.
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Basic E, Nabauer M. Changes in oral anticoagulation therapy over one year in 51,000 atrial fibrillation patients at risk for stroke: a practice-derived study. Thromb Haemost. 2019;119(6):882–893.
   PubMed Web of Science ®Google Scholar
• Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, et al. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thromb Haemost. 2017;117(7):1448–1454.
   PubMed Web of Science ®Google Scholar
• Rivera-Caravaca JM, Esteve-Pastor MA, Roldan V, et al. Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. Expert Opin Drug Saf. 2017;16(9):1051–1062.
   PubMed Web of Science ®Google Scholar
• Prochaska JH, Hausner C, Nagler M, et al. Subtherapeutic anticoagulation control under treatment with vitamin K-antagonists—data from a specialized coagulation service. Thromb Haemost. 2019;119(8):1347–1357.
   PubMed Web of Science ®Google Scholar
• Hwang J, Han S, Bae H-J, et al. NOAC adherence of patients with atrial fibrillation in the real world: dosing frequency matters? Thromb Haemost. 2020;120(2):306–313.
   PubMed Web of Science ®Google Scholar
• Pritchett RV, Bem D, Turner GM, et al. Improving the prescription of oral anticoagulants in atrial fibrillation: a systematic review. Thromb Haemost. 2019;119(2):294–307.
   PubMed Web of Science ®Google Scholar
• Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke. 2006;37(1):256–262.
   PubMed Web of Science ®Google Scholar
• Feigin VL, Lawes CM, Bennett DA, et al. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2003;2(1):43–53.
   PubMed Web of Science ®Google Scholar
• Banerjee G, Ambler G, Wilson D, et al. Baseline factors associated with early and late death in intracerebral haemorrhage survivors. Eur J Neurol. 2020;27(7):1257–1263.
   PubMed Web of Science ®Google Scholar
• Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. J Am Coll Cardiol. 2017;70(24):3042–3067.
   PubMed Web of Science ®Google Scholar
• Cervera Á, Amaro S, Chamorro Á. Oral anticoagulant-associated intracerebral hemorrhage. J Neurol. 2012;259(2):212–224.
   PubMed Web of Science ®Google Scholar
• Grysiewicz R, Gorelick PB. Incidence, mortality, and risk factors for oral anticoagulant–associated intracranial hemorrhage in patients with atrial fibrillation. J Stroke Cerebrovasc Dis. 2014;23(10):2479–2488.
   PubMed Web of Science ®Google Scholar
• Alonso A, Bengtson LGS, MacLehose RF, et al. Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin. Stroke. 2014;45(8):2286–2291.
   PubMed Web of Science ®Google Scholar
• Farasat S, Tsoi A, Lee K, et al. Outcomes of hemorrhagic stroke patients with atrial fibrillation or flutter. J Atr Fibrillation. 2019;11(6):2144.
   PubMedGoogle Scholar
• Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, high blood pressure research council, and the quality of care and outcomes in research interdisciplinary working group. Stroke. 2007;38(6):2001–2023.
   PubMed Web of Science ®Google Scholar
• Caceres JA, Goldstein JN. Intracranial hemorrhage. Emergency Medicine Clinics of North America. 2012;30(3):771–794.
   PubMed Web of Science ®Google Scholar
• Safatli DA, Gunther A, Schlattmann P, et al. Predictors of 30-day mortality in patients with spontaneous primary intracerebral hemorrhage. Surgical Neurology International. 2016;7(Suppl 19):S510–7.
   PubMedGoogle Scholar
• Bhatia R, Kumar G, Padma M, et al. A prospective study of in-hospital mortality and discharge outcome in spontaneous intracerebral hemorrhage. Neurol India. 2013;61(3):244–248.
   PubMed Web of Science ®Google Scholar
• Fang MC, Go AS, Chang Y, et al. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke. 2012;43(7):1795–1799.
   PubMed Web of Science ®Google Scholar
• Lopes RD, Guimaraes PO, Kolls BJ, et al. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood. 2017;129(22):2980–2987.
   PubMed Web of Science ®Google Scholar
• Nishtala PS, Jamieson HA, Hanger HC, et al. Examining the risks of major bleeding events in older people using antithrombotics. Cardiovasc Drugs Ther. 2019;33(3):323–329.
   PubMed Web of Science ®Google Scholar
• Zanella L, Zoppellaro G, Marigo L, et al. Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A case-control study. Cardiovascular Therapeutics. 2018;36(5):e12458.
   PubMed Web of Science ®Google Scholar
• Gurol ME. Nonpharmacological management of atrial fibrillation in patients at high intracranial hemorrhage risk. Stroke. 2018;49(1):247–254.
   PubMed Web of Science ®Google Scholar
• Chopard R, Piazza G, Hurwitz S, et al. Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients. J Thromb Thrombolysis. 2019;47(2):331–335.
   PubMed Web of Science ®Google Scholar
• Lehtola H, Palomaki A, Mustonen P, et al. Traumatic and spontaneous intracranial hemorrhage in atrial fibrillation patients on warfarin. Neurol Clin Pract. 2018;8(4):311–317.
   PubMedGoogle Scholar
• Esteve-Pastor MA, Rivera-Caravaca JM, Lip GYH. Hypertension and atrial fibrillation: balancing stroke and bleeding risks. Am J Hypertens. 2017;30(11):1063–1065.
   PubMed Web of Science ®Google Scholar
• Vemulapalli S, Inohara T, Kim S, et al. Blood pressure control and cardiovascular outcomes in patients with atrial fibrillation (from the ORBIT-AF registry). Am J Cardiol. 2019;123(10):1628–1636.
   Web of Science ®Google Scholar
• Lehtola H, Hartikainen J, Hartikainen P, et al. How do anticoagulated atrial fibrillation patients who suffer ischemic stroke or spontaneous intracerebral hemorrhage differ? Clin Cardiol. 2018;41(5):608–614.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Otsuka T, Sagara K, et al. Effects of smoking on ischemic stroke, intracranial hemorrhage, and coronary artery events in Japanese patients with non-valvular atrial fibrillation. Int Heart J. 2017;58(4):506–515.
   PubMed Web of Science ®Google Scholar
• Crosta F, Desideri G, Marini C. Leukoaraiosis is an independent predictor of intracranial hemorrhage in patients with atrial fibrillation. J Thromb Thrombolysis. 2019;47(4):527–532.
   PubMed Web of Science ®Google Scholar
• Charidimou A, Karayiannis C, Song T-J, et al. Brain microbleeds, anticoagulation, and hemorrhage risk: meta-analysis in stroke patients with AF. Neurology. 2017;89(23):2317–2326.
   PubMed Web of Science ®Google Scholar
• Selim M, Diener H-C. Atrial fibrillation and microbleeds. Stroke. 2017;48(10):2660–2664.
   PubMed Web of Science ®Google Scholar
• Shuaib A, Akhtar N, Kamran S, et al. Management of cerebral microbleeds in clinical practice. Transl Stroke Res. 2018;10(5):449-457.
   Web of Science ®Google Scholar
• Tiili P, Putaala J, Mehtälä J, et al. Poor quality of warfarin treatment increases the risk of all types of intracranial hemorrhage in atrial fibrillation. Circ J. 2019;83(3):540–547.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al., 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the heart rhythm society. Circulation. 2014;130(23):e199–267.
   PubMed Web of Science ®Google Scholar
• Pandey AK, Xu K, Zhang L, et al. Lower versus standard INR targets in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Thromb Haemost. 2020;120(3):484–494.
   PubMed Web of Science ®Google Scholar
• McDowell T-Y, Lawrence J, Florian J, et al. Relationship between international normalized ratio and outcomes in modern trials with warfarin controls. Pharmacotherapy. 2018;38(9):899–906.
   PubMed Web of Science ®Google Scholar
• Chao T-F, Guo Y. Should we adopt a standard international normalized ratio range of 2.0 to 3.0 for Asian patients with atrial fibrillation? An appeal for evidence-based management, not eminence-based recommendations. Thromb Haemost. 2020;120(3):366–368.
   PubMed Web of Science ®Google Scholar
• Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, et al. Estimated effectiveness and safety of nonvitamin K antagonist oral anticoagulants compared with optimally acenocoumarol anticoagulated “real-world” in patients with atrial fibrillation. Am J Cardiol. 2018;122(5):785–792.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Baro E, Zhang R, et al. Comparative stroke, bleeding, and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132(5):596–604.e11.
   Web of Science ®Google Scholar
• Bracey A, Shatila W, Wilson J. Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence. Ther Adv Cardiovasc Dis. 2018;12(12):361–380.
   PubMedGoogle Scholar
• Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non–vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality. JAMA. 2018;319(5):463–473.
   PubMed Web of Science ®Google Scholar
• Denas G, Gennaro N, Ferroni E, et al. Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: propensity score matched cohort study. Int J Cardiol. 2017;249:198–203.
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Lioutas V-A, Varelas P, et al. Direct oral anticoagulant– vs vitamin K antagonist–related nontraumatic intracerebral hemorrhage. Neurology. 2017;89(11):1142–1151.
   PubMed Web of Science ®Google Scholar
• Lioutas V-A, Goyal N, Katsanos AH, et al. Clinical outcomes and neuroimaging profiles in nondisabled patients with anticoagulant-related intracerebral hemorrhage. Stroke. 2018;49(10):2309–2316.
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Katsanos AH, Seiffge DJ, et al. Fatal intracranial haemorrhage occurring after oral anticoagulant treatment initiation for secondary stroke prevention in patients with atrial fibrillation. Eur J Neurol. 2020. DOI:10.1111/ene.14280.
   Web of Science ®Google Scholar
• Lee S-R, Choi E-K, Kwon S, et al. Oral anticoagulation in Asian patients with atrial fibrillation and a history of intracranial hemorrhage. Stroke. 2020;51(2):416–423.
   PubMed Web of Science ®Google Scholar
• Chao T-F, Liu C-J, Lin Y-J, et al. Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study. Circulation. 2018;138(1):37–47.
   PubMed Web of Science ®Google Scholar
• Zoppellaro G, Zanella L, Denas G, et al. Different safety profiles of oral anticoagulants in very elderly non-valvular atrial fibrillation patients. A retrospective propensity score matched cohort study. Int J Cardiol. 2018;265:103–107.
   PubMed Web of Science ®Google Scholar
• Malik AH, Yandrapalli S, Aronow WS, et al. Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients >75 years of age. Am J Cardiol. 2019;123(12):2051–2057.
   PubMed Web of Science ®Google Scholar
• Chao T-F, Chiang C-E, Liao J-N, et al. Comparing the effectiveness and safety of nonvitamin k antagonist oral anticoagulants and warfarin in elderly Asian patients with atrial fibrillation: a nationwide cohort study. Chest. 2020;157(5):1266–1277.
   PubMed Web of Science ®Google Scholar
• Alnsasra H, Haim M, Senderey AB, et al. Net clinical benefit of anticoagulant treatments in elderly patients with nonvalvular atrial fibrillation: experience from the real world. Heart Rhythm. 2019;16(1):31–37.
   PubMed Web of Science ®Google Scholar
• Hohmann C, Hohnloser SH, Jacob J, et al. Non-vitamin K oral anticoagulants in comparison to phenprocoumon in geriatric and non-geriatric patients with non-valvular atrial fibrillation. Thromb Haemost. 2019;119(6):971–980.
   PubMed Web of Science ®Google Scholar
• Bennaghmouch N, de Veer A, Bode K, et al. Efficacy and safety of the use of non–vitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation and concomitant aspirin therapy. Circulation. 2018;137(11):1117–1129.
   PubMed Web of Science ®Google Scholar
• Douros A, Renoux C, Yin H, et al. Concomitant Use of direct oral anticoagulants with antiplatelet agents and the risk of major bleeding in patients with nonvalvular atrial fibrillation. Am J Med. 2019;132(2):191–9.e12.
   PubMed Web of Science ®Google Scholar
• Lee H-F, Chan Y-H, Chang S-H, et al. Effectiveness and safety of non–vitamin K antagonist oral anticoagulant and warfarin in cirrhotic patients with nonvalvular atrial fibrillation. J Am Heart Assoc. 2019;8(5):e011112.
   PubMed Web of Science ®Google Scholar
• Patel T, Patel V. Review: dOACs reduce intracranial hemorrhage more than warfarin in AF with CKD. Ann Intern Med. 2018;168(4):Jc18.
   PubMed Web of Science ®Google Scholar
• Kimachi M, Furukawa TA, Kimachi K, et al. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst Rev. 2017;11(11):Cd011373.
   PubMed Web of Science ®Google Scholar
• Tritschler T, Castellucci LA. It’s time for head-to-head trials with direct oral anticoagulants. Thromb Res. 2019;180:64–69.
   PubMed Web of Science ®Google Scholar
• López-López JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016;116(11):975–986.
   PubMedGoogle Scholar
• Wong JM, Maddox TM, Kennedy K, et al. Comparing major bleeding risk in outpatients with atrial fibrillation or flutter by oral anticoagulant type (from the national cardiovascular disease registry’s practice innovation and clinical excellence registry). Am J Cardiol. 2020;125(10):1500–1507.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49(12):2933–2944.
   PubMed Web of Science ®Google Scholar
• Borre ED, Goode A, Raitz G, et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost. 2018;118(12):2171–2187.
   PubMed Web of Science ®Google Scholar
• Esteve-Pastor MA, Rivera-Caravaca JM, Shantsila A, et al. Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED score. The AMADEUS trial. Thrombosis and Haemostasis. 2017;117(12):2261–2266.
   PubMed Web of Science ®Google Scholar
• Chao T-F, Lip GYH, Lin Y-J, et al. Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study. Int J Cardiol. 2018;254:157–161.
   PubMed Web of Science ®Google Scholar
• Guo Y, Zhu H, Chen Y, et al. Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation. Am J Med. 2018;131(2):185–192.
   PubMed Web of Science ®Google Scholar
• Gallego P, Roldan V, Torregrosa JM, et al. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2012;5(2):312–318.
   PubMed Web of Science ®Google Scholar
• Roldan V, Marin F, Manzano-Fernandez S, et al. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2013;62(23):2199–2204.
   PubMed Web of Science ®Google Scholar
• Apostolakis S, Lane DA, Buller H, et al. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Thromb Haemost. 2013;110(5):1074–1079.
   PubMed Web of Science ®Google Scholar
• Sideris S, Archontakis S, Latsios G, et al. Biomarkers associated with bleeding risk in the setting of atrial fibrillation. Curr Med Chem. 2019;26(5):824-836.
   Google Scholar
• Hijazi Z, Oldgren J, Andersson U, et al. Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: insights from the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Am Heart J. 2017;190:94–103.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Oldgren J, Lindbäck J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016;387(10035):2302–2311.
   PubMed Web of Science ®Google Scholar
• Esteve-Pastor MA, Roldán V, Rivera-Caravaca JM, et al. The use of biomarkers in clinical management guidelines: a critical appraisal. Thromb Haemost. 2019;119(12):1901–1919.
   PubMed Web of Science ®Google Scholar
• Camelo-Castillo A, Rivera-Caravaca JM, Marín F, et al. Predicting adverse events beyond stroke and bleeding with the ABC-stroke and ABC-Bleeding scores in patients with atrial fibrillation: the murcia AF project. Thromb Haemost. 2020.
   PubMedGoogle Scholar
• Roldan V, Rivera-Caravaca JM, Shantsila A, et al. Enhancing the ‘real world’ prediction of cardiovascular events and major bleeding with the CHA2DS2-VASc and HAS-BLED scores using multiple biomarkers. Ann Med. 2018;50(1):26–34.
   PubMed Web of Science ®Google Scholar
• Rivera-Caravaca JM, Marín F, Vilchez JA, et al. Refining stroke and bleeding prediction in atrial fibrillation by adding consecutive biomarkers to clinical risk scores. Stroke. 2019;50(6):1372-1379.
   PubMed Web of Science ®Google Scholar
• Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, et al. Long-term bleeding risk prediction in ‘real world’ patients with atrial fibrillation: comparison of the HAS-BLED and ABC-bleeding risk scores. The Murcia Atrial Fibrillation Project. Thromb Haemost. 2017;117(10):1848–1858.
   PubMed Web of Science ®Google Scholar
• Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393.
   PubMed Web of Science ®Google Scholar
• Doherty JU, Gluckman TJ, Hucker WJ, et al. ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology clinical expert consensus document task force. J Am Coll Cardiol. 2017;69(7):871–898.
   PubMed Web of Science ®Google Scholar
• Chang S-H, Chou I-J, Yeh Y-H, et al. Association between use of non–vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. Jama. 2017;318(13):1250–1259.
   PubMed Web of Science ®Google Scholar
• European-Medicines-Agency-(EMA). Pradaxa (R). Dabigatran summary of product characteristics. [cited 2019 Apr 11]. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf
   Google Scholar
• European-Medicines-Agency-(EMA). Xarelto (R). Rivaroxaban summary of product characteristics. [cited 2019 Apr 11]. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf.
   Google Scholar
• European-Medicines-Agency-(EMA). Lixiana (R). Edoxaban summary of product characteristics. [cited 2019 Apr 11]. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf.
   Google Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386–399.
   PubMed Web of Science ®Google Scholar
• Best JG, Bell R, Haque M, et al. Atrial fibrillation and stroke: a practical guide. Pract Neurol. 2019;19(3):208–224.
   PubMedGoogle Scholar
• Spoerke N, Michalek J, Schreiber M, et al. Crystalloid resuscitation improves survival in trauma patients receiving low ratios of fresh frozen plasma to packed red blood cells. J Trauma. 2011;71(Suppl 2):S380–3.
   PubMedGoogle Scholar
• Sprigg N, Flaherty K, Appleton JP, et al. Tranexamic acid for hyperacute primary intracerebral haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet. 2018;391(10135):2107–2115.
   PubMed Web of Science ®Google Scholar
• Parry-Jones AR, Di Napoli M, Goldstein JN, et al. Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage. Ann Neurol. 2015;78(1):54–62.
   PubMed Web of Science ®Google Scholar
• Bucko AM, van Veen JJ, Makris M. Is fresh frozen plasma as good as prothrombin complex concentrate for vitamin K antagonist reversal in acute intracerebral hemorrhage? Ann Neurol. 2016;79(2):331–332.
   PubMed Web of Science ®Google Scholar
• Majeed A, Ågren A, Holmström M, et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood. 2017;130(15):1706–1712.
   PubMed Web of Science ®Google Scholar
• Gerner ST, Kuramatsu JB, Sembill JA, et al. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol. 2018;83(1):186–196.
   PubMed Web of Science ®Google Scholar
• Arachchillage DRJ, Alavian S, Griffin J, et al. Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding. Br J Haematol. 2019;184(5):808–816.
   PubMed Web of Science ®Google Scholar
• Kerebel D, Joly L-M, Honnart D, et al. A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal. Crit Care. 2013;17(1):R4.
   PubMed Web of Science ®Google Scholar
• Kim C, Cottingham L, Eberwein K, et al. Comparison of hemostatic outcomes in patients receiving fixed-dose vs. weight-based 4-factor prothrombin complex concentrate. J Emerg Med. 2020. DOI:10.1016/j.jemermed.2020.04.049
   Web of Science ®Google Scholar
• Niessner A, Tamargo J, Morais J, et al. Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis.. Eur Heart J. 2017;38(22):1710–1716.
   PubMed Web of Science ®Google Scholar
• Pollack CV Jr., Reilly PA, van Ryn J, et al., Idarucizumab for dabigatran reversal — full cohort analysis. N Engl J Med. 2017;377(5):431–441.
   PubMed Web of Science ®Google Scholar
• Fuh L, Sin JH, Goldstein JN, et al. Reversal of oral anticoagulants for intracerebral hemorrhage patients: best strategies. Semin Respir Crit Care Med. 2017;38(6):726–736.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost. 2015;113(5):931–942.
   PubMed Web of Science ®Google Scholar
• Pollack CV Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511–520.
   PubMed Web of Science ®Google Scholar
• Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol. 2018;15(5):273–281.
   PubMed Web of Science ®Google Scholar
• Heo Y-A. Andexanet alfa: first global approval. Drugs. 2018;78(10):1049–1055.
   PubMed Web of Science ®Google Scholar
• Agency EM. Ondexxya 2019 [cited 2020 Mar 30]. Available from: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/ondexxya.
   Google Scholar
• Hunt BJ, Levi M. Urgent reversal of vitamin K antagonists. BMJ. 2018;360:j5424.
   PubMedGoogle Scholar
• Yasaka M. New insights into nonvitamin K antagonist oral anticoagulants’ reversal of intracerebral hemorrhage. Front Neurol Neurosci. 2015;37:93–106.
   PubMedGoogle Scholar
• Connolly SJ, Milling TJ Jr., Eikelboom JW, et al., Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131–1141.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380(14):1326–1335.
   PubMed Web of Science ®Google Scholar
• Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371(22):2141–2142.
   PubMed Web of Science ®Google Scholar
• Kalathottukaren MT, Creagh AL, Abbina S, et al. Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors. Blood Advances. 2018;2(16):2104–2114.
   PubMed Web of Science ®Google Scholar
• Molina CA, Selim MH. The dilemma of resuming anticoagulation after intracranial hemorrhage: little evidence facing big fears. Stroke. 2011;42(12):3665–3666.
   PubMed Web of Science ®Google Scholar
• Proietti M, Mujovic N, Potpara TS. Optimizing stroke and bleeding risk assessment in patients with atrial fibrillation: a balance of evidence, practicality and precision. Thromb Haemost. 2018;118(12):2014–2017.
   PubMed Web of Science ®Google Scholar
• Murthy SB, Diaz I, Wu X, et al. Risk of arterial ischemic events after intracerebral hemorrhage. Stroke. 2020;51(1):137–142.
   PubMed Web of Science ®Google Scholar
• Lip GYH. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J. 2013;34(14):1041–1049.
   PubMed Web of Science ®Google Scholar
• Redfors B, Gray WA, Lee RJ, et al. Patients with atrial fibrillation who are not on anticoagulant treatment due to increased bleeding risk are common and have a high risk of stroke. JACC Clin Electrophysiol. 2017;3(12):1369–1376.
   PubMedGoogle Scholar
• Lip GY, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. J Thromb Haemost. 2016;14(9):1711–1714.
   PubMed Web of Science ®Google Scholar
• Guo Y, Lane DA, Chen Y, et al. Regular bleeding risk assessment associated with reduction in bleeding outcomes: the mAFA-II randomized trial. Am J Med. 2020. DOI:10.1016/j.amjmed.2020.03.019
   PubMed Web of Science ®Google Scholar
• Chan K-H, Ka-Kit Leung G, Lau -K-K, et al. Predictive value of the HAS-BLED score for the risk of recurrent intracranial hemorrhage after first spontaneous intracranial hemorrhage. World Neurosurg. 2014;82(1–2):e219–23.
   PubMed Web of Science ®Google Scholar
• Banerjee G, Wilson D, Ambler G, et al. Longer term stroke risk in intracerebral haemorrhage survivors. J Neurol Neurosurg 2020;jnnp-2020-323079. jnnp-2020-323079. DOI:10.1136/jnnp-2020-323079.
   Web of Science ®Google Scholar
• Lip GYH, Lane DA. Matching the NOAC to the patient: remember the modifiable bleeding risk factors. J Am Coll Cardiol. 2015;66(21):2282–2284.
   PubMed Web of Science ®Google Scholar
• Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, et al. Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. Sci Rep. 2017;7(1):12066.
   PubMedGoogle Scholar
• Kuramatsu JB, Gerner ST, Schellinger PD, et al., Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. Jama. 2015;313(8):824–836.
   PubMed Web of Science ®Google Scholar
• da Silva IRF, Frontera JA. Resumption of anticoagulation after intracranial hemorrhage. Curr Treat Options Neurol. 2017;19(11):39.
   PubMed Web of Science ®Google Scholar
• Lane DA, Aguinaga L, Blomström-Lundqvist C, et al. Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace. 2015;17(12):1747–1769.
   PubMed Web of Science ®Google Scholar
• Rechenmacher SJ, Fang JC. Bridging anticoagulation: primum non nocere. J Am Coll Cardiol. 2015;66(12):1392–1403.
   PubMed Web of Science ®Google Scholar
• Rios SJ, Rivera-Caravaca JM, Aroca-Valverde C, et al. Efficacy and safety of peri-procedural bridging therapy with low molecular weight heparin in atrial fibrillation patients under vitamin K antagonists. QJM. 2019;112(3):183–188.
   PubMed Web of Science ®Google Scholar
• Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373(9):823–833.
   PubMed Web of Science ®Google Scholar
• Nielsen PB, Larsen TB, Skjoth F, et al. Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation. 2015;132(6):517–525.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Yu J, Carcel C, et al. Resuming anticoagulants after anticoagulation-associated intracranial haemorrhage: systematic review and meta-analysis. BMJ Open. 2018;8(5):e019672.
   PubMed Web of Science ®Google Scholar
• Proietti M, Romiti GF, Romanazzi I, et al. Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: A systematic review and meta-analysis. Int J Cardiol. 2018;261:84–91.
   PubMed Web of Science ®Google Scholar
• Hawkes MA, Rabinstein AA. Anticoagulation for atrial fibrillation after intracranial hemorrhage: A systematic review. Neurol Clin Pract. 2018;8(1):48–57.
   PubMedGoogle Scholar
• Murthy SB, Gupta A, Merkler AE, et al., Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis. Stroke. 2017;48(6):1594–1600.
   PubMed Web of Science ®Google Scholar
• Kuramatsu JB, Huttner HB. Management of oral anticoagulation after intracerebral hemorrhage. Int J Stroke. 2019;14(3):238–246.
   PubMed Web of Science ®Google Scholar
• Perreault S, Côté R, White-Guay B, et al. Anticoagulants in older patients with nonvalvular atrial fibrillation after intracranial hemorrhage. Journal of Stroke. 2019;21(2):195–206.
   PubMed Web of Science ®Google Scholar
• Pappas MA, Burke JF. Net clinical benefit of anticoagulation for atrial fibrillation following intracerebral hemorrhage. Vascular Medicine. 2020;25(1):55–59.
   PubMed Web of Science ®Google Scholar
• Nielsen PB, Larsen TB, Skjoth F, et al. Outcomes associated with resuming warfarin treatment after hemorrhagic stroke or traumatic intracranial hemorrhage in patients with atrial fibrillation. JAMA Intern Med. 2017;177(4):563–570.
   PubMed Web of Science ®Google Scholar
• Witt DM, Clark NP, Martinez K, et al., Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage. Thromb Res. 2015;136(5):1040–1044.
   PubMed Web of Science ®Google Scholar
• Korompoki E, Filippidis FT, Nielsen PB, et al. Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. Neurology. 2017;89(7):687–696.
   PubMed Web of Science ®Google Scholar
• Nielsen PB, Skjoth F, Sogaard M, et al. Non–vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with intracerebral hemorrhage. Stroke. 2019;50(4):939–946.
   PubMed Web of Science ®Google Scholar
• Shoamanesh A, Miller JE NOACs for stroke prevention in patients with atrial fibrillation and previous ICH (NASPAF-ICH) 2016. [cited 2020 Jun 22]. Available from: http://clinicaltrials.gov/show/NCT02998905.
   Google Scholar
• RESTART-Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet. 2019;393(10191):2613–2623.
   PubMed Web of Science ®Google Scholar
• Al-Shahi Salman R, Minks DP, Mitra D, et al. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurol. 2019;18(7):643–652.
   PubMed Web of Science ®Google Scholar
• Steiner T, Al-Shahi Salman R, Beer R, et al., European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke. 2014;9(7):840–855.
   PubMed Web of Science ®Google Scholar
• Hemphill JC 3rd, Greenberg SM, Anderson CS, et al., Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46(7):2032–2060.
   PubMed Web of Science ®Google Scholar
• Li Y-G, Lip GYH. Anticoagulation resumption after intracerebral hemorrhage. Curr Atheroscler Rep. 2018;20(7):32.
   PubMed Web of Science ®Google Scholar
• Becattini C, Sembolini A, Paciaroni M. Resuming anticoagulant therapy after intracerebral bleeding. Vascular Pharmacology. 2016;84:15–24.
   PubMed Web of Science ®Google Scholar
• Kato Y, Hayashi T, Suzuki K, et al. Resumption of direct oral anticoagulants in patients with acute spontaneous intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2019;28(10):104292.
   PubMed Web of Science ®Google Scholar
• Park Y-A, Uhm J-S, Pak H-N, et al. Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage. Heart Rhythm. 2016;13(9):1794–1802.
   PubMed Web of Science ®Google Scholar
• Newman TV, Chen N, He M, et al. Effectiveness and safety of restarting oral anticoagulation in patients with atrial fibrillation after an intracranial hemorrhage: analysis of medicare part D claims data from 2010–2016. Am J Cardiovasc Drugs. 2019. DOI:10.1007/s40256-019-00388-8
   PubMed Web of Science ®Google Scholar
• Pennlert J, Overholser R, Asplund K, et al., Optimal timing of anticoagulant treatment after intracerebral hemorrhage in patients with atrial fibrillation. Stroke. 2017;48(2):314–320.
   PubMed Web of Science ®Google Scholar
• Paciaroni M, Agnelli G. Should oral anticoagulants be restarted after warfarin-associated cerebral haemorrhage in patients with atrial fibrillation? Thromb Haemost. 2014;111(1):14–18.
   PubMed Web of Science ®Google Scholar
• Xu Y, Shoamanesh A, Schulman S, et al. Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: global survey of the practices of neurologists, neurosurgeons and thrombosis experts. PLoS One. 2018;13(1):e0191137.
   PubMed Web of Science ®Google Scholar
• Al-Shahi Salman R, Adamczuk K Start or stop anticoagulants randomised trial (SoSTART). 2017. [updated 2018 Jun 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT03153150.
   Google Scholar
• van Nieuwenhuizen KM, van der Worp HB, Algra A, et al. Apixaban versus antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral haemorrhage in patients with atrial fibrillation (APACHE-AF): study protocol for a randomised controlled trial. Trials. 2015;16(1):393.
   PubMedGoogle Scholar
• Schreuder FHBM, van der Worp HB Apixaban after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation (APACHE-AF). 2015. [[Updated 2018 Dec 5; cited 2020 Jun 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02565693.
   Google Scholar
• Veltkamp RE Prevention of stroke in intracerebral haemorrhage survivors with atrial fibrillation (PRESTIGE-AF). 2019 [updated 2020 May 26; cited 2020 Jun 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT03996772?cond=PRESTIGE-AF&draw=2&rank=1.
   Google Scholar
• Shoamanesh A EdoxabaN foR intracranial hemorrhage survivors with atrial fibrillation (ENRICH-AF) (ENRICH-AF). 2019 [updated 2019 Oct 29; cited 2020 Jun 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT03950076?cond=ENRICH-AF&draw=2&rank=1.
   Google Scholar
• Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61(2):755–759.
   PubMed Web of Science ®Google Scholar
• Ding WY, Mandrola J, Gupta D. Left atrial appendage occlusion: past, present and future. Thromb Haemost. 2020.
   PubMed Web of Science ®Google Scholar
• Nielsen-Kudsk JE, Johnsen SP, Wester P, et al. Left atrial appendage occlusion versus standard medical care in patients with atrial fibrillation and intracerebral haemorrhage: a propensity score-matched follow-up study. EuroIntervention. 2017;13(3):371–378.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2019;74(1):104–132.
   PubMed Web of Science ®Google Scholar
• Badhwar V, Rankin JS, Damiano RJ Jr., et al. The society of thoracic surgeons 2017 clinical practice guidelines for the surgical treatment of atrial fibrillation. Ann Thorac Surg. 2017;103(1):329–341.
   PubMed Web of Science ®Google Scholar
• Renou P, Thambo J-B, Iriart X, et al. Left atrial appendage closure in patients with atrial fibrillation and previous intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2017;26(3):545–551.
   PubMed Web of Science ®Google Scholar
• Hutt E, Wazni OM, Saliba WI, et al. Left atrial appendage closure device implantation in patients with prior intracranial hemorrhage. Heart Rhythm. 2018;16(5):663-668.
   PubMed Web of Science ®Google Scholar
• Moussa Pacha H, Al-Khadra Y, Soud M, et al. Percutaneous devices for left atrial appendage occlusion: A contemporary review. World Journal of Cardiology. 2019;11(2):57–70.
   PubMed Web of Science ®Google Scholar
• Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. Europace. 2019.
   Web of Science ®Google Scholar
• Rivera-Caravaca JM, Esteve-Pastor MA, Marin F, et al. A propensity score matched comparison of clinical outcomes in atrial fibrillation patients taking vitamin K Antagonists: comparing the “real-world” vs clinical trials. Mayo Clin Proc. 2018;93(8):1065–1073.
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen C, Goette A, Nielsen PB, et al. ’Real-world’ observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). Europace. 2020;22(5):831–832.
   PubMed Web of Science ®Google Scholar
• Majeed A, Kim Y-K, Roberts RS, et al. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke. 2010;41(12):2860–2866.
   PubMed Web of Science ®Google Scholar
• Ottosen TP, Grijota M, Hansen ML, et al., Use of antithrombotic therapy and long-term clinical outcome among patients surviving intracerebral hemorrhage. Stroke. 2016;47(7):1837–1843.
   PubMed Web of Science ®Google Scholar
• Poli L, Grassi M, Zedde M, et al., Anticoagulants resumption after warfarin-related intracerebral haemorrhage: the multicenter study on cerebral hemorrhage in Italy (MUCH-Italy). Thromb Haemost. 2018;118(3):572–580.
   PubMed Web of Science ®Google Scholar